FLSM
Frazier Life Sciences Management Portfolio holdings
AUM
$2.5B
This Quarter Return
-3.63%
1 Year Return
+52.94%
3 Year Return
+530.54%
5 Year Return
–
10 Year Return
–
AUM
$2.14B
AUM Growth
+$2.14B
(-9.8%)
Cap. Flow
-$56.2M
Cap. Flow
% of AUM
-2.63%
Top 10 Holdings %
Top 10 Hldgs %
61.97%
Holding
57
New
7
Increased
13
Reduced
4
Closed
8
Top Buys
| 1 |
Disc Medicine
IRON
|
$43.7M |
| 2 |
Erasca
ERAS
|
$38.3M |
| 3 |
AnaptysBio
ANAB
|
$31.7M |
| 4 |
Ultragenyx Pharmaceutical
RARE
|
$17.5M |
| 5 |
Savara
SVRA
|
$16.8M |
Top Sells
Sector Composition
| 1 | Healthcare | 99.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Trevi Therapeutics
TRVI
$871M
| $22M | 1.03% |
7,381,090
| – | – |
|
|
SLN
27
Silence Therapeutics
SLN
$237M
| $21.8M | 1.02% |
1,148,591
| – | – |
|
|
28
Ultragenyx Pharmaceutical
RARE
$3.04B
| $17.5M | 0.82% |
+425,000
| New | +$17.5M |
|
|
AUTL
29
Autolus Therapeutics
AUTL
$383M
| $16.1M | 0.75% |
4,623,324
| – | – |
|
|
CERE
30
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $16.1M | 0.75% |
393,000
| – | – |
|
|
MREO
31
Mereo BioPharma
MREO
$275M
| $15.8M | 0.74% |
+4,401,371
| New | +$15.8M |
|
32
Immatics
IMTX
$662M
| $13.4M | 0.63% |
+1,152,456
| New | +$13.4M |
|
33
Tyra Biosciences
TYRA
$657M
| $13.3M | 0.62% |
832,220
| – | – |
|
34
MacroGenics
MGNX
$121M
| $12.8M | 0.6% |
3,010,727
+539,023
| +22% | +$2.29M |
|
35
Applied Therapeutics
APLT
$73.7M
| $10.7M | 0.5% |
2,286,135
+333,278
| +17% | +$1.56M |
|
36
Puma Biotechnology
PBYI
$258M
| $9.98M | 0.47% |
3,062,558
+246,264
| +9% | +$803K |
|
37
89bio
ETNB
$1.37B
| $8.01M | 0.37% |
1,000,000
| – | – |
|
|
ELEV
38
DELISTED
Elevation Oncology
ELEV
| $7.99M | 0.37% |
+2,958,579
| New | +$7.99M |
|
39
Cogent Biosciences
COGT
$1.83B
| $7.9M | 0.37% |
936,576
| – | – |
|
40
Acadia Pharmaceuticals
ACAD
$4.34B
| $7.64M | 0.36% |
470,338
| – | – |
|
41
Arvinas
ARVN
$580M
| $7.6M | 0.36% |
285,331
| – | – |
|
42
Adverum Biotechnologies
ADVM
$68.2M
| $7.34M | 0.34% |
1,069,244
| – | – |
|
43
Allogene Therapeutics
ALLO
$249M
| $6.68M | 0.31% |
2,867,750
| – | – |
|
44
AN2 Therapeutics
ANTX
$35.3M
| $4.49M | 0.21% |
2,088,889
+700,000
| +50% | +$1.51M |
|
45
NewAmsterdam Pharma Company N.V. Warrant
NAMSW
$64M
| $4.36M | 0.2% |
500,333
| – | – |
|
46
Design Therapeutics
DSGN
$339M
| $4M | 0.19% |
+1,195,179
| New | +$4M |
|
47
Immunocore
IMCR
$1.78B
| $3.69M | 0.17% |
+108,762
| New | +$3.69M |
|
48
Metagenomi
MGX
$67.2M
| $1M | 0.05% |
245,692
-33,333
| -12% | -$136K |
|
49
Aclaris Therapeutics
ACRS
$223M
| $291K | 0.01% |
264,377
| – | – |
|
|
ALPN
50
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| – | – |
-3,131,008
| Closed | -$124M |
|